Drug Trial Radar · NCT06051721
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
May 10, 2024
Primary completion
Oct 14, 2025
Study completion Aug 5, 2026
Sponsor
- Lead sponsor
- Cybin IRL LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials
- First posted
- Sep 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.
Conditions
- Generalized Anxiety Disorder
Interventions
CYB004Drug
CYB004 is a synthetic deuterated N, N-Dimethyltryptamine (DMT) analog.
PsychotherapyBehavioral
Manualized psychotherapy (called EMBARK) performed by facilitators
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hamilton Anxiety Rating Scale (HAM-A)Time frame: Screening (Day-63 and Day-1), Day 2, Day 8, Day 21, Day 23, Day 29, Day 43, Day 64, Day 85, Day 169, Day 266, and End of Treatment (Day 364)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Research Centers of America
Hollywood, Florida
Innovative Clinical Research, Inc.
Miami Lakes, Florida
CenExel ACMR
Atlanta, Georgia
iResearch Atlanta
Decatur, Georgia
Uptown Research Institute
Chicago, Illinois
Cedar Clinical Research
Murray, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.